Company Secretary resigns; Q2 profit rises to Rs 39.9 crore

Key managerial personnel resignedManagement Changes View source PDF Explain this filing

SMSPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.1%Reaction day

₹523.95

prior close

₹527.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is usedpendingvs market: pending

Pharmaceuticals peers, median of 171sector+0.5%-1.6% vs sector

On the reaction day the stock moved 1.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.3

10m

-2.8

15m

-1.3

30m

+0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.1pendingpending+0.5-1.6

Next day

———+0.4—

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 171Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved Q2 FY27 results and a leadership change. Company Secretary and Compliance Officer Thirumalesh Tumma resigned for personal reasons, effective 4 November 2026. Manohar Mollama, with over 16 years in corporate governance, takes over from 5 November. Consolidated Q2 revenue was Rs 316.1 crore, up from Rs 242.4 crore a year ago, and net profit Rs 39.9 crore versus Rs 25.3 crore. Half-year revenue Rs 523.1 crore, profit Rs 60.8 crore.

Likely market impact

Strong profit growth should support the stock, but the company secretary change may draw some governance attention.